Should Australia Ban the Use of Genetic Test Results in Life Insurance?

Under current Australian regulation, life insurance companies can require applicants to disclose all genetic test results, including results from research or direct-to-consumer tests. Life insurers can then use this genetic information in underwriting and policy decisions for mutually rated products...

Full description

Saved in:
Bibliographic Details
Main Authors: Jane Tiller (Author), Margaret Otlowski (Author), Paul Lacaze (Author)
Format: Book
Published: Frontiers Media S.A., 2017-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_a302202c4cb5419099a2e45bcaadc8c5
042 |a dc 
100 1 0 |a Jane Tiller  |e author 
700 1 0 |a Margaret Otlowski  |e author 
700 1 0 |a Paul Lacaze  |e author 
245 0 0 |a Should Australia Ban the Use of Genetic Test Results in Life Insurance? 
260 |b Frontiers Media S.A.,   |c 2017-12-01T00:00:00Z. 
500 |a 2296-2565 
500 |a 10.3389/fpubh.2017.00330 
520 |a Under current Australian regulation, life insurance companies can require applicants to disclose all genetic test results, including results from research or direct-to-consumer tests. Life insurers can then use this genetic information in underwriting and policy decisions for mutually rated products, including life, permanent disability, and total income protection insurance. Over the past decade, many countries have implemented moratoria or legislative bans on the use of genetic information by life insurers. The Australian government, by contrast, has not reviewed regulation since 2005 when it failed to ensure implementation of recommendations made by the Australian Law Reform Commission. In that time, the Australian life insurance industry has been left to self-regulate its use of genetic information. As a result, insurance fears in Australia now are leading to deterred uptake of genetic testing by at-risk individuals and deterred participation in medical research, both of which have been documented. As the potential for genomic medicine grows, public trust and engagement are critical for successful implementation. Concerns around life insurance may become a barrier to the development of genomic health care, research, and public health initiatives in Australia, and the issue should be publicly addressed. We argue a moratorium on the use of genetic information by life insurers should be enacted while appropriate longer term policy is determined and implemented. 
546 |a EN 
690 |a genetics 
690 |a insurance 
690 |a genetic discrimination 
690 |a regulation 
690 |a legislation 
690 |a moratorium 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n Frontiers in Public Health, Vol 5 (2017) 
787 0 |n http://journal.frontiersin.org/article/10.3389/fpubh.2017.00330/full 
787 0 |n https://doaj.org/toc/2296-2565 
856 4 1 |u https://doaj.org/article/a302202c4cb5419099a2e45bcaadc8c5  |z Connect to this object online.